Fusion Antibodies (LON:FAB) Stock Price Down 11.3% – Here’s Why

Fusion Antibodies plc (LON:FAB)’s stock price was down 11.3% during mid-day trading on Thursday . The stock traded as low as GBX 4.33 ($0.06) and last traded at GBX 4.35 ($0.06). Approximately 954,842 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 1,116,575 shares. The stock had previously closed at GBX 4.90 ($0.06).

Fusion Antibodies Price Performance

The firm has a market capitalization of £4.14 million, a price-to-earnings ratio of -120.00 and a beta of 0.49. The company’s 50 day moving average is GBX 3.61 and its 200-day moving average is GBX 3.51. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40.

Insider Activity at Fusion Antibodies

In related news, insider Simon Gordon Douglas acquired 150,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was purchased at an average cost of GBX 3 ($0.04) per share, for a total transaction of £4,500 ($5,876.21). In related news, insider Simon Gordon Douglas acquired 150,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was purchased at an average cost of GBX 3 ($0.04) per share, for a total transaction of £4,500 ($5,876.21). Also, insider Adrian Kinkaid purchased 120,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, with a total value of £3,600 ($4,700.97). In the last ninety days, insiders bought 448,553 shares of company stock worth $1,429,387. Insiders own 11.39% of the company’s stock.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.